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 Background Method Conclusion 
Mesothelioma is an aggressive cancer that develops from mesothelial 
cells, the protective cells that cover many internal organs1. The primary 
risk factor is asbestos and it takes 30~40 years for mesothelioma to 
develop after asbestos exposure6. During the long developing period, an 
accumulation of multiple genetic alterations results in a very 
heterogeneous tumor at the molecular level. Clinical data indicates 
mesothelioma is resistant to almost all conventional cancer therapies. 
Chemotherapy combinations for mesothelioma can offer median 
survival of only one year4. The poor therapeutic outcome is due to the 
lack of predictive biomarkers and variability in tumor biology at the 
molecular level among the patients. Previous researches suggested that 
PI3K/AKT/mTOR pathway is constitutively activated in many tumor and 
identified as an oncogenic driver3. It is is an intracellular pathway that 
plays essential roles in cell function including protein synthesis and 
growth control. Recent studies indicated  genetic variants in the this 
pathway predict the response to chemotherapy of solid tumor and 
tumor recurrence of head and neck cancer patients3. PI3K/AKT/mTOR 
pathway also serves as a drug target for cancer treatment. The dual 
PI3K/mTOR inhibitor PKI-587 has been tested in vitro, showing 
preclinical efficacy in 50 diverse human tumor cell lines2. Based on these 
developments the hypothesis below was formed. 
Hypothesis 
Genetic variability of the key molecules involved in PI3K/mTOR pathway 
will predict the response to standard therapy for mesothelioma and 
serve as  predictive biomarkers for using PI3K/mTOR pathway inhibitors 
as combination therapy with standard treatment. And the dual inhibitor 
PKI-587 in this pathway can be a promising drug for mesothelioma 
treatment.  
 
 
 
 
 
• rs1003857, rs1130214, rs2230730 and rs2498804 in the PI3K pathway may serve 
as potential biomarkers to predict the therapeutic outcomes of mesothelioma 
patients to standard treatment. 
• Rs1003857 (T>C) is significantly associated with overall survival of mesothelioma 
patients with a hazard ratio 0.4, indicated that  patients have a longer survival with 
at least one minor allele (C).  rs1003857 is located in the coding region of RPS6KA2, 
which encodes ribosomal protein S6 kinase. Even though rs1003857 doesn’t alter 
the amino acid sequence, it may decrease the stability of mRNA or create splicing 
variants, thus affect the RPS6KA2 expression.    
• Rs2230730 (A>G) minor allele is significantly associated with shorter survival with 
the hazard ratio 1.7. rs2230730 is also located in the coding region of RPS6KA2, 
however it may increase the stability of mRNA, which leads to overexpression of 
ribosomal protein S6 kinase. 
• Patients with minor allele of rs2498804 (G>T) have a shorter survival based on the 
hazard ratio 1.8. This SNP is located in 3’ UTR of AKT1 gene, which may alter the 
AKT1 expression by changing the miRNA binding sites and result in the 
overexpression of AKT protein. Previous research also showed rs2498804 is 
potential biomarker for brain metastases in non-small cell lung cancer8.  
• Survival data showed heterozygote patients in rs1130214 have shorter survival 
than homozygote patients. This SNP is located in 5’ UTR of AKT1 gene, which may 
enhance the binding affinity between promoter and DNA, leading to 
overexpression of AKT1.  
• Based on the hazard ratio, patients with TT form of rs1003857, GG form of 
rs2230730, TT form of rs249804 and GT form of rs1130214 may need to use 
PI3K/AKT pathway inhibitor combined with standard treatment to obtained a 
better clinical outcome in mesothelioma.  
• PKI-587 is a promising PI3K pathway inhibitor for mesothelioma patients, which 
inhibit phosphorylation of 4EBP1 to hinder the cell proliferation. 
• Combination therapy with PKI-587 and standard care can be a potential treatment 
strategy for selected mesothelioma patients, who are supposed to have a worse 
response to standard care according to the SNPs analysis .                                               
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Result 
Further direction 
• Ribosomal protein S6 kinase and AKT expression level in the mesothelioma 
patients should be studied. 
• The mechanism that these SNPs can alter the gene expression should be further 
studied.  
• Explore the mechanism of resistance to PKI-587 in mesothelioma resistance cell 
line (H2596). 
• Study the combination therapy with other pathway inhibitor (MAPK inhibitor) to 
overcome the PKI-587 resistance in mesothelioma.  
 
 
 
• DNA isolation was performed employing QIAamp DNA FFPE tissue kit(cat. No. 56404) from paraffin-embedded 
tissues of mesothelioma patients.  
• SNP selection and analysis: tagging SNPs within each gene (coding region, 5’UTR and 3’ UTR) were selected with 
a minor allele frequency greater than 5% using samples from European ancestry (CEPH) genotyped by the 
HapMap project.  
• Cell culture: H513, H2373, H2461 and H2596 mesothelioma cell lines were maintained on RPMI 1640 media 
containing 10% calf serum and 1% antibiotics.  
• Cell viability assay: Cell viability was measured by cell count kit-8(CCK-8) after 72 h drug (PKI-587) treatment. 
• Western blot: Cells were exposed to 400 nM PKI-587 for 0, 24h, 48h respectively. Antibodies were from Cell 
signaling Technology. Total and phosphorylation forms of each protein are visualized from western blots. 
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Figure 17: Overview of the PI3K/AKT/mTOR pathway and drug targets. PI3K serves as dual 
inhibitor, which inhibits both PI3K and mTOR , thus limits the activity of downstream effectors.  
SNP Gene Protein Positio
n 
Type of 
mutation 
Minor 
allele 
Minor allele 
frequency   
Hazard ratio 
(95% Cl) 
P-value 
rs1003857 
 RPS6KA2 
Ribosomal 
protein S6.K 
coding Nonsense C 0.21 0.4 (0.2-0.7) 0.004* 
rs2230730 RPS6KA2 
 
Ribosomal 
protein S6.K 
coding Nonsense G 0.38 1.7 (1.1-2.7) 0.027* 
rs2498804 AKT1 AKT1 3’UTR         - T 0.30 1.8 (1.0-3.3) 0.058 
rs1130214 AKT1 AKT1 5’UTR         - T 0.27 1.3 (0.9-1.8) 0.240 
Table 1: Characteristics of SNPs in the PI3K/AKT/mTOR pathway, which showed the best association between minor 
allele and  survival.  
 
Figure 2: Association analysis between minor allele and survival. SNPs- rs1003857, rs2230730, rs2498804, rs1130214 are 
associated with overall survival in forty mesothelioma patients under standard treatment. 
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Figure 3 :Cell viability for mesothelioma cell lines 
following PKI-587 treatment.  
Figure 4: Phosphorylation status after PKI-587 
treatment. Protein phosphorylation changes are 
revealed after 24, 48 h  treatment with 400nM PKI-
587 in mesothelioma cells. 
